Discussion of Zoetis manpower and management performance that can provide insight into the enterprise performance. Note, an employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Zoetis future performance. Zoetis employes about 10000 people. The company is managed by 25 executives with total tenure of roughly 116 years, averanging almost 4.0 years of service per executive having 1.0 employee per reported executive. See also Your Current Watchlist.
Zoetis Management EffectivenessThe company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
Zoetis Workforce Comparison
Zoetis is rated below average in number of employees category among related companies. The total workforce of Drug Manufacturers - Specialty & Generic industry is at this time estimated at about 62,674. Zoetis retains roughly 10,000 in number of employees claiming about 16% of equities under Drug Manufacturers - Specialty & Generic industry.
Zoetis Profit MarginsThe company has Net Profit Margin of 22.74 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 38.49 % which entails that for every 100 dollars of revenue it generated 0.38 of operating income.
Zoetis Insider Trading
Zoetis Benchmark Summation
|Juan Alaix Chief Executive Officer, Director|
|Michael McCallister Non-Executive Independent Chairman of the Board|
|Roman Trawicki Executive Vice President and Presidentident of Global Manufacturing and Supply|
|Kristin Peck Executive Vice President and Group President, U.S. Operations, Business Development and Strategy|
|Roxanne Lagano Executive Vice President, Chief Human Resources Officer and Communications|
|Clinton Lewis Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics|
|Stefan Weiskopf Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand|
|Catherine Knupp Executive Vice President, President - Research and Development|
|Alejandro Bernal Executive Vice President and Area President of the Europe, Africa and Middle East region|
|Joyce Lee Executive Vice President and Area President of the Canada and Latin America region|
|Glenn David Chief Financial Officer, Executive Vice President|
|Sandra Beaty Executive Vice President - Corporate Affairs|
|Andrew Fenton Executive Vice President and Chief Digital and Technology Officer|
|Heidi Chen Executive Vice President General Counsel, Corporate Secretary|
|Paul Herendeen CFO and Executive VP|
|William Steere Independent Director|
|Linda Rhodes Independent Director|
|Frank DAmelio Independent Director|
|Robert Scully Independent Director|
|Sanjay Khosla Independent Director|
|Paul Bisaro Independent Director|
|Willie Reed Independent Director|
|William Doyle Director|
|Gregory Norden Independent Director|
|Louise Parent Independent Director|